NTT
21.5.2020 21:02:11 CEST | Business Wire | Press release
In preparation for the rescheduled 104th Indianapolis 500 presented by Gainbridge, NTT Corporation (NTT) today announced enhancements to Indianapolis Motor Speedway (IMS) that will accelerate smart technologies to improve the INDYCAR fan experience and safety when the Greatest Spectacle in Racing returns Sunday, Aug. 23, 2020.
“We are excited that when fans arrive at IMS for the Indy 500 they will be greeted with an improved, world-class and one-of-a-kind trip to the Racing Capital of the World,” said Mark Miles, Penske Entertainment Corp. President & CEO. “The future of sports will be driven by the ability to use technology to enhance fan experience, safety and convenience. NTT is helping IMS and INDYCAR find new and exciting ways to blend tradition with innovation and ultimately preserve and further The Greatest Spectacle in Racing’s history of discovery and progress.”
NTT will leverage the company’s Accelerate Smart data platform to power a 100-foot wide Media Wall at the base of the landmark Pagoda building, which will provide fans with access to data-driven race insights in real-time. The debut of the highly visible Media Wall will capture fans’ attention with 3D experiences, visualization of 143 data points from every car and multiple live feeds throughout the track. NTT’s Accelerate Smart platform will also use machine learning to indicate where cars should be on the track and predict their next move, while AI will pinpoint the best on-track battles and highlight head-to-head matchups in real-time with pit predictions, top speeds and more.
“NTT’s Accelerate Smart platform is super-charging efforts to significantly enhance the fan-experience at IMS. At this year’s Indy 500, the platform’s statistics and information will power a transformed Pagoda Plaza experience, providing key and engaging competition insights never previously available to in-venue fans in real time,” said Indianapolis Motor Speedway President, J. Douglas Boles. “In addition, NTT will also boost our safety and security grid, contributing to the well-being of spectators and event participants at the world’s largest single-day sporting event.”
At IMS, NTT’s Accelerate Smart solution includes safety and security measures that will offer more effective event security operations and oversight. Data analytics and insights will provide crowd and vehicle congestion detection and alerts that predict rates based on trends at the gates and tunnels. The digital-enabled, enhanced safety and security will establish a model to promote a consistent experience at IMS, as well as all INDYCAR venue events.
“The future of sport means providing fans with digital-first content, better access to technology and leveraging venues, such as IMS, to engage fans through new channels,” said Akira Shimada, Senior Executive Vice President, NTT. “Our Accelerate Smart data platform allows us to digitally transform INDYCAR’S fan engagement to retain its standing as a leader in motorsports, while also creating a safer race day experience.”
Penske and IMS leadership have made connectivity a key theme of investment to allow fans access to as much data and information in real-time as possible. As part of the digital focus, NTT has also evolved the INDYCAR Mobile app powered by NTT DATA to provide fans a second screen to view live in-car camera video during races, track weather forecasts, create and follow fantasy teams, watch on-demand highlights and more.
NTT’s is committed to accelerating the future of smart racing and creating the next generation of INDYCAR fans who want to enjoy the sport through a more digital experience. This is in part why NTT, a global information technology and communications leader, has been the title sponsor of the NTT INDYCAR SERIES since 2019, as well as the Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway, Indianapolis 500 and NASCAR’s the Brickyard 400.
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom